Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults

Benjamin Young, Margaret A Fischl, Helene M. Wilson, Tyler S. Finn, Erin H. Jensen, Mark J. DiNubile, Robert K. Zeldin

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Low-dose ritonavir can boost plasma levels of indinavir, thereby enhancing its antiretroviral activity despite less frequent dosing. In this open-label, noncomparative, 24-week trial with a 24-week extension phase, HIV-infected protease inhibitor (PI)- and lamivudine-naive adults received indinavir/ritonavir 800 mg/100 mg plus stavudine and lamivudine every 12 hours. The proportions of patients achieving plasma HIV RNA (vRNA) <400 and <50 copies/mL were analyzed with data as observed (DAO) and intention-to-treat models using generalized estimating equations (GEE) or counting noncompleters as failures (NC = F). Eighty-nine patients (80% men) with a median age of 36 years and mean baseline vRNA levels and CD4 counts of 5.01 log10 copies/mL and 269 cells/mm3 were enrolled. The proportions (95% confidence interval [CI]) of patients achieving vRNA <400 copies/mL were 93% (84%, 98%), 78% (67%, 86%), and 68% (57%, 78%) at week 24 for DAO, GEE, and NC = F analyses, respectively; the corresponding results at week 48 were 95% (84%, 99%), 65% (53%, 76%), and 45% (35%, 57%). Most patients with vRNA 400 had <50 copies/mL. At week 48, baseline vRNA decreased by >2 log10 copies/mL and CD4 counts increased by approximately 200 cells/mm3. Five patients (6%) experienced serious drug-related adverse experiences. Twenty patients (23%) discontinued therapy due to adverse experiences. In this study, twice-daily indinavir 800 mg/ritonavir 100 mg with two nucleoside reverse transcriptase inhibitors provided potent viral suppression and immunologic reconstitution in many PI-naive patients.

Original languageEnglish
Pages (from-to)478-482
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume31
Issue number5
StatePublished - Dec 15 2002

Fingerprint

Indinavir
HIV Protease Inhibitors
Ritonavir
Lamivudine
Stavudine
Reverse Transcriptase Inhibitors
CD4 Lymphocyte Count
Protease Inhibitors
Nucleosides
HIV
RNA
Pharmaceutical Preparations

Keywords

  • Indinavir
  • Pharmacokinetic enhancement
  • Protease inhibitors
  • Ritonavir

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. / Young, Benjamin; Fischl, Margaret A; Wilson, Helene M.; Finn, Tyler S.; Jensen, Erin H.; DiNubile, Mark J.; Zeldin, Robert K.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, 15.12.2002, p. 478-482.

Research output: Contribution to journalArticle

Young, Benjamin ; Fischl, Margaret A ; Wilson, Helene M. ; Finn, Tyler S. ; Jensen, Erin H. ; DiNubile, Mark J. ; Zeldin, Robert K. / Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. In: Journal of Acquired Immune Deficiency Syndromes. 2002 ; Vol. 31, No. 5. pp. 478-482.
@article{c5a3e2f563594d7981b888d01776efed,
title = "Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults",
abstract = "Low-dose ritonavir can boost plasma levels of indinavir, thereby enhancing its antiretroviral activity despite less frequent dosing. In this open-label, noncomparative, 24-week trial with a 24-week extension phase, HIV-infected protease inhibitor (PI)- and lamivudine-naive adults received indinavir/ritonavir 800 mg/100 mg plus stavudine and lamivudine every 12 hours. The proportions of patients achieving plasma HIV RNA (vRNA) <400 and <50 copies/mL were analyzed with data as observed (DAO) and intention-to-treat models using generalized estimating equations (GEE) or counting noncompleters as failures (NC = F). Eighty-nine patients (80{\%} men) with a median age of 36 years and mean baseline vRNA levels and CD4 counts of 5.01 log10 copies/mL and 269 cells/mm3 were enrolled. The proportions (95{\%} confidence interval [CI]) of patients achieving vRNA <400 copies/mL were 93{\%} (84{\%}, 98{\%}), 78{\%} (67{\%}, 86{\%}), and 68{\%} (57{\%}, 78{\%}) at week 24 for DAO, GEE, and NC = F analyses, respectively; the corresponding results at week 48 were 95{\%} (84{\%}, 99{\%}), 65{\%} (53{\%}, 76{\%}), and 45{\%} (35{\%}, 57{\%}). Most patients with vRNA 400 had <50 copies/mL. At week 48, baseline vRNA decreased by >2 log10 copies/mL and CD4 counts increased by approximately 200 cells/mm3. Five patients (6{\%}) experienced serious drug-related adverse experiences. Twenty patients (23{\%}) discontinued therapy due to adverse experiences. In this study, twice-daily indinavir 800 mg/ritonavir 100 mg with two nucleoside reverse transcriptase inhibitors provided potent viral suppression and immunologic reconstitution in many PI-naive patients.",
keywords = "Indinavir, Pharmacokinetic enhancement, Protease inhibitors, Ritonavir",
author = "Benjamin Young and Fischl, {Margaret A} and Wilson, {Helene M.} and Finn, {Tyler S.} and Jensen, {Erin H.} and DiNubile, {Mark J.} and Zeldin, {Robert K.}",
year = "2002",
month = "12",
day = "15",
language = "English",
volume = "31",
pages = "478--482",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "5",

}

TY - JOUR

T1 - Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults

AU - Young, Benjamin

AU - Fischl, Margaret A

AU - Wilson, Helene M.

AU - Finn, Tyler S.

AU - Jensen, Erin H.

AU - DiNubile, Mark J.

AU - Zeldin, Robert K.

PY - 2002/12/15

Y1 - 2002/12/15

N2 - Low-dose ritonavir can boost plasma levels of indinavir, thereby enhancing its antiretroviral activity despite less frequent dosing. In this open-label, noncomparative, 24-week trial with a 24-week extension phase, HIV-infected protease inhibitor (PI)- and lamivudine-naive adults received indinavir/ritonavir 800 mg/100 mg plus stavudine and lamivudine every 12 hours. The proportions of patients achieving plasma HIV RNA (vRNA) <400 and <50 copies/mL were analyzed with data as observed (DAO) and intention-to-treat models using generalized estimating equations (GEE) or counting noncompleters as failures (NC = F). Eighty-nine patients (80% men) with a median age of 36 years and mean baseline vRNA levels and CD4 counts of 5.01 log10 copies/mL and 269 cells/mm3 were enrolled. The proportions (95% confidence interval [CI]) of patients achieving vRNA <400 copies/mL were 93% (84%, 98%), 78% (67%, 86%), and 68% (57%, 78%) at week 24 for DAO, GEE, and NC = F analyses, respectively; the corresponding results at week 48 were 95% (84%, 99%), 65% (53%, 76%), and 45% (35%, 57%). Most patients with vRNA 400 had <50 copies/mL. At week 48, baseline vRNA decreased by >2 log10 copies/mL and CD4 counts increased by approximately 200 cells/mm3. Five patients (6%) experienced serious drug-related adverse experiences. Twenty patients (23%) discontinued therapy due to adverse experiences. In this study, twice-daily indinavir 800 mg/ritonavir 100 mg with two nucleoside reverse transcriptase inhibitors provided potent viral suppression and immunologic reconstitution in many PI-naive patients.

AB - Low-dose ritonavir can boost plasma levels of indinavir, thereby enhancing its antiretroviral activity despite less frequent dosing. In this open-label, noncomparative, 24-week trial with a 24-week extension phase, HIV-infected protease inhibitor (PI)- and lamivudine-naive adults received indinavir/ritonavir 800 mg/100 mg plus stavudine and lamivudine every 12 hours. The proportions of patients achieving plasma HIV RNA (vRNA) <400 and <50 copies/mL were analyzed with data as observed (DAO) and intention-to-treat models using generalized estimating equations (GEE) or counting noncompleters as failures (NC = F). Eighty-nine patients (80% men) with a median age of 36 years and mean baseline vRNA levels and CD4 counts of 5.01 log10 copies/mL and 269 cells/mm3 were enrolled. The proportions (95% confidence interval [CI]) of patients achieving vRNA <400 copies/mL were 93% (84%, 98%), 78% (67%, 86%), and 68% (57%, 78%) at week 24 for DAO, GEE, and NC = F analyses, respectively; the corresponding results at week 48 were 95% (84%, 99%), 65% (53%, 76%), and 45% (35%, 57%). Most patients with vRNA 400 had <50 copies/mL. At week 48, baseline vRNA decreased by >2 log10 copies/mL and CD4 counts increased by approximately 200 cells/mm3. Five patients (6%) experienced serious drug-related adverse experiences. Twenty patients (23%) discontinued therapy due to adverse experiences. In this study, twice-daily indinavir 800 mg/ritonavir 100 mg with two nucleoside reverse transcriptase inhibitors provided potent viral suppression and immunologic reconstitution in many PI-naive patients.

KW - Indinavir

KW - Pharmacokinetic enhancement

KW - Protease inhibitors

KW - Ritonavir

UR - http://www.scopus.com/inward/record.url?scp=0037114806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037114806&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 478

EP - 482

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 5

ER -